The UK is set to become the first country in the world to pay drug companies a fixed fee for supplying antibiotics in an effort to tackle the growing global crisis over resistance to the drugs.
The aim is to give companies a better incentive to develop new antibiotics, which would be held back to treat patients who really need them, while restraining overprescribing that leads microbes to develop drug resistance.
Health experts estimate that antimicrobial resistance (AMR) kills more than one million people a year worldwide, putting pressure on the medical profession to cut back use of antibiotics in all but the most serious cases.
您已閱讀16%（636字），剩余84%（3348字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。